← All companies
About this company
Alopecia areata (AA) is a chronic autoimmune condition that causes random hair loss, up to full baldness. It affects 4.2M children globally and imposes immense psychological burden and exclusion. Coacillium, Legacy’s drug candidate, is the first in development for the treatment of Pediatric AA, and is currently in Phase 2/3 trial. So far, Coacillium has shown unparalleled safety and clinical efficacy looks promising. Approval is expected in 2023 by EMA and 2024 by FDA. Pediatric AA represents a €0.8B market opportunity, where Coacillium will be the only approved drug. Subsequently, Coacillium will be extended to the Adult AA market, a €2B market.